Overall Survival (OS) - Percentage of Participants With an Event Baseline (BL), Days 1, 8, 15, 22, 43, 64, 85, 106, 127, and every 21 days until the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis [clinicaltrials_resource:082b4ac3f8c8e9eeef3b3bb8788673ad]
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Overall Survival (OS) - Percentage of Participants With an Event Baseline (BL), Days 1, 8, 15, 22, 43, 64, 85, 106, 127, and every 21 days until the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis [clinicaltrials_resource:082b4ac3f8c8e9eeef3b3bb8788673ad]
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up.
Bio2RDF identifier
082b4ac3f8c8e9eeef3b3bb8788673ad
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:082b4ac3f8c8e9eeef3b3bb8788673ad
measure [clinicaltrials_vocabulary:measure]
Overall Survival (OS) - Percentage of Participants With an Event
time frame [clinicaltrials_vocabulary:time-frame]
Baseline (BL), Days 1, 8, 15, ...... 2nd interim efficacy analysis
description
OS was defined as the time fro ...... or the date of last follow-up.
identifier
clinicaltrials_resource:082b4ac3f8c8e9eeef3b3bb8788673ad
title
Overall Survival (OS) - Percen ...... 2nd interim efficacy analysis
@en
type
label
Overall Survival (OS) - Percen ...... b4ac3f8c8e9eeef3b3bb8788673ad]
@en